Product Category

Chemyo Sarms carries a curated library of research-grade nootropic compounds — synthetic agents studied for their interactions with neurological systems including neurotransmitter pathways, neurotrophin signaling, dopaminergic activity, and cellular NAD+ metabolism. Every compound is independently third-party tested with batch-specific Certificate of Analysis documentation confirming identity, purity, and concentration. The term "nootropic" broadly refers to compounds studied for effects on cognitive function — including memory consolidation, learning acquisition, attention, and neuroprotection. Unlike SARMs, which target androgen receptors, nootropic research compounds work through diverse neurological and metabolic mechanisms. They do not act on the hypothalamic-pituitary-gonadal axis and are not associated with hormonal suppression. Our nootropics research library features three mechanistically distinct compound categories. Noopept (GVS-111) is a synthetic dipeptide nootropic with a published preclinical literature documenting AMPA receptor modulation and upregulation of BDNF and NGF expression in rodent models — neurotrophins central to synaptic plasticity and neuroprotection. Bromantane (Ladasten) is a dopaminergic actoprotector registered for clinical use in Russia since 1996, studied for its unusual mechanism of stimulating dopamine biosynthesis via upregulation of tyrosine hydroxylase and DOPA decarboxylase — distinct from standard reuptake-inhibiting stimulants. 5-AMINO-1MQ is a small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor studied for its role in NAD+ metabolism, mitochondrial function, and the intersection of metabolic and neuroprotective biology. All compounds are supplied as research chemicals strictly for laboratory and preclinical research use. They are not intended for human consumption and are not approved by the FDA for therapeutic use. For a detailed overview of how these compounds work, what mechanisms they target, and what the published literature documents, see our Complete Guide to Nootropics. Third-Party Testing — Our Standard Every batch in our nootropics library is independently tested by a third-party laboratory before release. Batch-specific COA documentation confirms HPLC-verified identity, purity percentage, and concentration — the minimum standard for reproducible research.
Chemyo Sarms carries a curated library of research-grade nootropic compounds — synthetic agents studied for their interactions with neurological systems including neurotransmitter pathways, neurotrophin signaling, dopaminergic activity, and cellular NAD+ metabolism. Every compound is independently third-party tested with batch-specific Certificate of Analysis documentation confirming identity, purity, and concentration. The term "nootropic" broadly refers to compounds studied for effects on cognitive function — including memory consolidation, learning acquisition, attention, and neuroprotection. Unlike SARMs, which target androgen receptors, nootropic research compounds work through diverse neurological and metabolic mechanisms. They do not act on the hypothalamic-pituitary-gonadal axis and are not associated with hormonal suppression. Our nootropics research library features three mechanistically distinct compound categories. Noopept (GVS-111) is a synthetic dipeptide nootropic with a published preclinical literature documenting AMPA receptor modulation and upregulation of BDNF and NGF expression in rodent models — neurotrophins central to synaptic plasticity and neuroprotection. Bromantane (Ladasten) is a dopaminergic actoprotector registered for clinical use in Russia since 1996, studied for its unusual mechanism of stimulating dopamine biosynthesis via upregulation of tyrosine hydroxylase and DOPA decarboxylase — distinct from standard reuptake-inhibiting stimulants. 5-AMINO-1MQ is a small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor studied for its role in NAD+ metabolism, mitochondrial function, and the intersection of metabolic and neuroprotective biology. All compounds are supplied as research chemicals strictly for laboratory and preclinical research use. They are not intended for human consumption and are not approved by the FDA for therapeutic use. For a detailed overview of how these compounds work, what mechanisms they target, and what the published literature documents, see our Complete Guide to Nootropics. Third-Party Testing — Our Standard Every batch in our nootropics library is independently tested by a third-party laboratory before release. Batch-specific COA documentation confirms HPLC-verified identity, purity percentage, and concentration — the minimum standard for reproducible research.